Latest News
News Functions
Additional Functions
29 June 2015
Prothena Corporation plc
Prothena Announces Addition of Seasoned Executive to Board of Directors
17 June 2015
Prothena Corporation plc
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson’s Disease
16 June 2015
Prothena Corporation plc
Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
12 June 2015
Prothena Corporation plc
Prothena’s NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
Prothena Corporation plc
Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
9 June 2015
Prothena Corporation plc
Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases
8 June 2015
Prothena Corporation plc
Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson’s Disease and Movement Disorders
2 June 2015
Prothena Corporation plc
Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting
21 May 2015
Prothena Corporation plc
Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association
13 May 2015
Prothena Corporation plc
Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO Annual Meeting
5 May 2015
Prothena Corporation plc
Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update
4 May 2015
Prothena Corporation plc
The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for Parkinson’s Disease
28 April 2015
Prothena Corporation plc
Prothena to Present at Upcoming Investor Healthcare Conferences
23 April 2015
Prothena Corporation plc
Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences
8 April 2015
Prothena Corporation plc
Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares
6 April 2015
Prothena Corporation plc
Prothena Announces Proposed Offering of Ordinary Shares
19 March 2015
Prothena Corporation plc
Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson’s Disease
5 March 2015
Prothena Corporation plc
Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Guidance and R&D Update
19 February 2015
Prothena Corporation plc
Prothena to Report Fourth Quarter and Full Year 2014 Financial Results and Host Webcast and Conference Call on March 5
18 February 2015
Prothena Corporation plc
Prothena to Present at the 2015 RBC Capital Markets’ Healthcare Conference in New York on February 25
15 December 2014
Prothena Corporation plc
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis
8 December 2014
Prothena Corporation plc
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
2 December 2014
Prothena Corporation plc
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis
3 November 2014
Prothena Corporation plc
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress
26 August 2014
Prothena Corporation plc
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress
18 August 2014
Prothena Corporation plc
Dr. Dale Schenk to Discuss Parkinson’s Disease at 2014 Rejuvenation Biotechnology Conference
31 July 2014
Prothena Corporation plc
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson’s Disease
25 June 2014
Prothena Corporation plc
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
23 June 2014
Prothena Corporation plc
Prothena Announces Proposed Offering of Ordinary Shares
27 May 2014
Prothena Corporation plc
Prothena to Present at the Jefferies 2014 Global Healthcare Conference in New York